Osmoregulation of vasopressin secretion in the insulin-withdrawn streptozotocin-treated diabetic rat.
To investigate whether hyperglycaemic ketoacidotic diabetic rats continue to osmoregulate the secretion of arginine vasopressin (AVP), male Wistar rats were injected with streptozotocin (150 mg/kg body weight). Rats rendered diabetic were maintained on protamine-zinc insulin (PZI) for 11 days (insulin-treated rats; n = 35), after which PZI was withdrawn for 72 h in half the rats (insulin-withdrawn rats). Insulin-withdrawn and -treated rats were divided into two groups; one was injected i.p. with distilled water (20 ml/kg) and the other with hypertonic saline (500 mmol NaCl/l; 20 ml/kg), and killed 30 min after injection. Insulin-withdrawn rats (water loaded and osmotically stimulated) were hyperglycaemic (16.5 +/- 0.8 and 16.5 +/- 0.9 mmol glucose/l respectively) and ketotic (2077 +/- 664 and 1474 +/- 170 mumol acetoacetate/l respectively). Insulin-treated rats were euglycaemic and non-ketotic. Osmotic manipulation caused similar changes in plasma sodium in both insulin-withdrawn and -treated rats. Plasma AVP was low in the water-loaded rats (0.6 +/- 0.1 and 4.5 +/- 0.9 pmol/l in the insulin-treated and -withdrawn rats respectively) and increased in rats injected with hypertonic saline (1.2 +/- 1.8 and 35.2 +/- 17.9 pmol/l respectively). There was no evidence of hypotension and hypovolaemia in any group of rats. Linear regression analysis defined the functions: plasma AVP = 2.56 (plasma Na-141), r = +0.63, P less than 0.01 for hyperglycaemic ketotic rats; plasma AVP = 0.83 (plasma Na-146), r = +0.78, P less than 0.001 for insulin-treated animals. The slopes and abscissal intercepts were significantly (P less than 0.05) different.(ABSTRACT TRUNCATED AT 250 WORDS)
Charlton
J A
JA
Department of Medicine, Medical School, Newcastle-upon-Tyne.
Thompson
C J
CJ
Palmer
J M
JM
Thornton
S
S
Baylis
P H
PH
D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000628:therapy; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D014882:Water-Electrolyte Balance
D049528:Insulin, Long-Acting; D001127:Arginine Vasopressin